SR18662 (intraperitoneal injection; 5-10 mg/kg; daily or twice daily; 5 days injection, days break, and 5 days) effectively suppresses tumor growth in a mouse xenograft model^[1].

SR18662 (0-10 μM; 24-72 hours) markedly attenuates the growth and proliferation of colorectal cancer (CRC) cells compared to treatment with the vehicle control or ML264 alone. Its enhanced efficacy in reducing the viability of various CRC cell lines is notable^[1].

SR18662 (10 μM; 24-72 hours) induces a notable elevation in the quantity of apoptotic cells at both early and late stages in DLD-1 and HCT116 cells^[1].

SR18662, at 1 μM concentration over 72 hours, decreases the expression of cyclins (specifically cyclins E, A2, and B1), as well as components of the MAPK pathway (p-Erk) and the WNT signaling pathway (p-GSK3 β) in cells^[1].